Intellia Therapeutics

Intellia Therapeutics

Yahoo Finance • 19 hours ago

Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other c... Full story

Yahoo Finance • 17 days ago

Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast

Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases of $25.9M of CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), $24.4M of Meta Platforms (META [https://seek... Full story

Yahoo Finance • 30 days ago

Nike downgraded, Home Depot initiated: Wall Street's top analyst calls

Nike downgraded, Home Depot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compile... Full story

Yahoo Finance • 2 months ago

Cathie Wood Makes Striking Switch Between AI Stock Giants

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical dol... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $27.9 million of surging megacap stock

Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when she sees a new opportunity. That's what she did last week, pouring $27.9 million into Meta Platforms (META) as the company pushes deeper into AI. La... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $3.5 million of surging tech stock

Cathie Wood, chief of Ark Investment Management, often adds to her favorite stocks when prices swing. This time, according to an email shared with TheStreet, she's buying $3.5 million of Robinhood stock, reversing her recent sales as the... Full story

Yahoo Finance • 2 months ago

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its genetic source rather than primarily managing downstream symptoms. Unlike conventional therapies that may require chro... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $28.1 million of popular tech stock

Cathie Wood, head of Ark Investment Management, often adds to her favorite tech stocks when prices swing. This week, she's buying SpaceX (SPCX), continuing to build her position after the newly public stock went through a volatile stretch... Full story

Yahoo Finance • 4 months ago

Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis

Oselote/iStock via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Alnylam Pharma (ALNY [https://seekingalpha.com/symbol/ALNY]), and BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]), which market drugs for a... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan disease treatments. Intellia Therapeutics... Full story

Yahoo Finance • 5 months ago

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story

Yahoo Finance • 5 months ago

What Makes BioLife Solutions (BLFS) a Compelling Long-Term Hold?

Prosper Stars & Stripes, a long/short equity fund, recently released its first-quarter 2026 investor letter. A copy of the letter is available to download here. In Q1 2026, the portfolio underperformed with a net return of (-5.6%) compared... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026 HAELO manuscript simultaneously published in the New England Journal of Medici... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today ann... Full story

Yahoo Finance • 5 months ago

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Investors have long looked to Warren Buffett for investing inspiration. This is because the billionaire, as chief executive officer of Berkshire Hathaway for 60 years, led the company to market-beating returns over that time period. He did... Full story

Yahoo Finance • 5 months ago

Draft FDA guidance could be a boon for gene therapy developers

[Genetic Medicine And DNA Therapy] narvo vexar * The US FDA has issued draft guidance intended to accelerate the development of gene and cell therapies. * The agency hopes the document will enhance the R&D process for the treatments "... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today ann... Full story

Yahoo Finance • 6 months ago

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital raised the price target for Nextpowe... Full story